Pasithea Therapeutics (KTTA) Osake Kurssi

Pasithea Therapeutics Corp. is a biotechnology company focuses on the research and discovery of new and treatments for psychiatric and neurological disorders. The company is headquartered in Miami Beach, Florida and currently employs 15 full-time employees. The company went IPO on 2021-08-13. The firm is primarily focused on the discovery, research and development of treatments for Central Nervous System (CNS) disorders and RASopathies. The firm operates through two segments: Therapeutics and Clinics. Its Therapeutics segment performs activities related to the discovery, research, and development of treatments for CNS disorders and other diseases. Its Clinics segment provides business support services to anti-depression clinics in the United Kingdom and in the United States. Its therapeutic pipeline consists of four programs. Its lead product candidate, PAS-004, is a macrocyclic mitogen-activated protein kinase (MEK) inhibitor for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and Noonan syndrome, as well as lamin A/C (LMNA) cardiomyopathy and a number of oncology indications. Its other three programs are in the discovery stage.